Nymox has reported that NX-1207 has showed positive results when given to animals with hepatocellular carcinoma (HCC). NX-1207 is a novel drug in phase 3 development, for the treatment of benign prostatic hyperplasia (BPH).
The company said that in the experimental studies, cancers were significantly reduced in size after two local injections of NX-1207. The rodents in the studies had transplanted human HCC. These animals had an average tumor burden reduction of close to 50% after 20 days.
The company further plans to advance NX-1207 into human clinical trials for the treatment of HCC.
Moreover, the drug has been successful in a series of blinded controlled multi-center US clinical trials, where it has been found to produce improvements that are about double than reported for currently approved BPH drugs.
Follow-up studies have shown that many men showed continued benefit from a single NX-1207 treatment for two years or more.